

Apolipoproteins and Diabetic Retinopathy

In this issue of *Diabetes Care* Sasongko et al. (1) make the intriguing observation that apolipoprotein (apo)B and apoA-I, and particularly the apoB-to-apoA-I ratio, are related to the presence of diabetic retinopathy in a small cohort of type 1 and type 2 diabetic patients. Moreover, this ratio correlated with the retinopathy severity and also was a better predictor of retinopathy than traditional lipid measures such as total cholesterol, LDL or HDL cholesterol, or even the LDL-to-HDL cholesterol ratio.

This study raises many important questions. For example, why are these relationships between retinopathy and lipoproteins seen in this small study, whereas previous studies, some in much larger cohorts, have not shown a consistent relationship? Did measurement of apolipoproteins rather than the lipid components of the lipoproteins make the difference? Lipids and lipoproteins are well-accepted risk factors for macrovascular disease in diabetes via mechanisms that are reasonably well understood. However, do lipids and lipoproteins play a role in microvascular complications such as retinopathy in addition to better known risk factors such as diabetes duration, glycemic control, and hypertension? And if so, by what mechanisms does HDL protect and the apoB-containing lipoproteins increase the risk of retinopathy?

In the current study, stronger relationships were observed between retinopathy and apolipoproteins than with lipid components of the lipoproteins. ApoA-I is the major structural apolipoprotein present in HDL and is reflective of the number of HDL particles. A single molecule of apoB is present in LDL, as well as in VLDL, remnant lipoproteins (often present in the intermediate-density lipoprotein [IDL] density range) and lipoprotein (a) (Lp(a)), another atherogenic lipoprotein. Because each of these lipoproteins contains a single molecule of apoB, apoB concentration is a measure of the total number of these atherogenic particles. If these lipoproteins also have an adverse effect on microvascular complications such as retinopathy, apoB levels might be expected to show a better relationship

with retinopathy than individual measurements of LDL, VLDL, IDL, or Lp(a) lipids. Similarly, if HDL has protective properties in the eye as well as in the artery wall, apoA-I levels might be expected to be a better predictor of risk than HDL lipids, since HDL particles are very heterogeneous in composition.

The relationship between lipids and lipoproteins with atherosclerotic cardiovascular disease (CVD) might provide important clues to the relationship between lipoproteins and retinopathy. The earliest observed relationships were between plasma cholesterol and CVD (2–4). Later LDL cholesterol itself was found to be a strong predictor of CVD risk (5,6). Basic studies suggested many potential mechanisms by which LDL might be atherogenic, including the ability to be taken up and be retained in the artery wall, after which they can undergo various forms of modification, including oxidative modification and hydrolysis of components of the lipoprotein by enzymes such as secretory phospholipases and sphingomyelinase (7–13). Components of modified lipoproteins can damage arterial cells or be atherogenic by other mechanisms. However, the importance of LDL as a risk factor was only firmly established by randomized controlled clinical trials (RCTs) that demonstrated that LDL lowering reduced the risk of CVD (14–16). The role of HDL as an atheroprotective lipoprotein emerged at about the same time. Several mechanisms by which HDL might be atheroprotective (17,18) include its ability to promote reverse cholesterol transport, as well as its anti-inflammatory, antioxidant, and antithrombotic properties (19). However, RCTs have yet to clearly demonstrate a role for HDL in preventing CVD events. Although there is a clear association between triglycerides, which are transported in plasma as VLDL, and CVD (20), RCTs have yet to provide definitive evidence for their causal role in CVD. Because of this type of evidence, guidelines have generally focused on LDL lowering, although more recent guidelines have paid increasing attention to HDL and triglycerides (21).

The role of apolipoproteins in CVD risk is now receiving increasing attention. Correlations of apoB and apoA-I, as well as the ratio of apoB to apoA-I, with CVD risk are well described. Whether apolipoproteins are better CVD risk predictors than traditional lipid measurements remains controversial. In the Apolipoprotein-related Mortality Risk (AMORIS) trial, both apolipoproteins and traditional lipid measurements were predictive, but the apolipoproteins were slightly more significant, particularly in patients with lower LDL levels (22). The INTERHEART study showed that the apoB-to-apoA-I ratio was superior to any traditional cholesterol ratio in estimation of risk for acute myocardial infarction (23). Other studies have not shown apolipoproteins to be better predictors of CVD risk than traditional lipid measurements. For example, the apoB-to-apoA-I ratio was comparable with traditional lipid ratios in predicting CVD risk and did not improve upon the total cholesterol-to-HDL ratio in the Framingham cohort (24). Moreover, case control analysis of healthy participants from the European Prospective Investigation of Cancer (EPIC)-Norfolk study showed that apoB-to-apoA-I ratio was independently associated with CVD risk but did not add to existing measures of lipid analysis (25). Thus, although both traditional lipids and lipoproteins and apolipoprotein ratios are good CVD risk predictors, it remains to be seen whether apolipoprotein measurements will replace traditional risk factors in future CVD guidelines.

What about diabetes, lipoproteins, and CVD risk? Similar relationships appear to exist between lipoproteins and CVD risk as for individuals without diabetes. In the UK Prospective Diabetes Study (UKPDS), LDL cholesterol was the strongest predictor of risk (26). Other studies have shown that triglycerides and low HDL also are important risk predictors in diabetes (27). In the few studies in which apolipoproteins have been assessed in patients with diabetes, apoB-to-apoA-I ratio predicts CVD risk similar to that seen in nondiabetic cohorts. In the Collaborative Atorvastatin Diabetes Study

- development of ischaemic heart-disease. *Lancet* 1975;1:16–19
18. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am J Med* 1977;62:707–714
 19. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. *J Am Coll Cardiol* 2008; 51:2199–2211
 20. Austin MA. Plasma triglyceride and coronary heart disease. *Arterioscler Thromb* 1991;11:2–14
 21. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143–3421
 22. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. *Lancet* 2001;358:2026–2033
 23. McQueen MJ, Hawken S, Wang X, et al.; INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. *Lancet* 2008;372: 224–233
 24. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. *JAMA* 2007;298:776–785
 25. van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. *Ann Intern Med* 2007; 146:640–648
 26. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). *BMJ* 1998;316:823–828
 27. Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. *Diabetes* 1997;46:1354–1359
 28. Charlton-Menys V, Betteridge DJ, Colhoun H, et al. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). *Diabetologia* 2009;52:218–225
 29. Taskinen MR, Barter PJ, Ehnholm C, et al.; FIELD study investigators. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. *Diabetologia* 2010;53:1846–1855
 30. van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoom Study. *Diabetes Care* 2002;25:1320–1325
 31. Klein R, Sharrett AR, Klein BE, et al.; ARIC Group. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. *Ophthalmology* 2002;109:1225–1234
 32. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. *Invest Ophthalmol Vis Sci* 2004; 45:910–918
 33. Keech AC, Mitchell P, Summanen PA, et al.; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet* 2007;370:1687–1697
 34. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med* 2010;363:233–244